Close Menu

NEW YORK – 23andMe said on Thursday that it has signed an agreement to merge with VG Acquisition Corp., a special-purpose acquisition company sponsored by Virgin Group, with the ultimate purpose of becoming publicly traded through Virgin Acquisition's position on the New York Stock Exchange.

Once the transaction is complete, which the partners are estimating will occur in the second quarter, VGAC will change its NYSE ticker symbol and the combined company's shares will trade under the ticker symbol ME.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.